Weight Loss in Adults Using Semaglutide (Real-world Study)

Part of paid clinical trials in Seattle, Washington.

Sponsor
Novo Nordisk A/S
Study ID
NCT07627074
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.

Study Details

The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Key Dates

Start date
May 12, 2026
Status verified
May 2026
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
35,000 participants (estimated)

Arms

  • Arm: Semaglutide
    Adults initiating semaglutide in routine clinical care and assigned to 0.5, 1.0, 1.7 or 2.4 mg at approximately Week 20. Participants are followed from treatment initiation up to 68 weeks using data collected during routine clinical practice. No study-specific interventions, visits, or procedures are performed. Data are derived from secondary use of routinely collected healthcare data.

Primary Outcome Measure

Change in body weight [ Time Frame: From index date (day 0) to week 68 (day 476) ]

Central Contacts

Locations (1)

FacilityCityStateZIP
Novo Nordisk Investigational SiteSeattleWashington98039

Find similar trials in Seattle, WA

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Novo Nordisk Investigational Site· Seattle, WA

Related Studies